• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022

    12/22/22 10:00:36 AM ET
    $AGEN
    $ALC
    $APLD
    $BAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Ophthalmic Goods
    Health Care
    Get the next $AGEN alert in real time by email

    Upgrades

    According to DA Davidson, the prior rating for Helen Of Troy Ltd (NASDAQ:HELE) was changed from Neutral to Buy. Helen Of Troy earned $2.27 in the second quarter, compared to $2.65 in the year-ago quarter. The current stock performance of Helen Of Troy shows a 52-week-high of $249.08 and a 52-week-low of $82.94. Moreover, at the end of the last trading period, the closing price was at $97.25.

    See all analyst ratings upgrades.

    Downgrades

    For Nkarta Inc (NASDAQ:NKTX), Oppenheimer downgraded the previous rating of Outperform to Perform. In the third quarter, Nkarta showed an EPS of $0.58, compared to $0.68 from the year-ago quarter. The stock has a 52-week-high of $20.35 and a 52-week-low of $5.81. At the end of the last trading period, Nkarta closed at $5.88.

    Oppenheimer downgraded the previous rating for Fate Therapeutics Inc (NASDAQ:FATE) from Outperform to Perform. In the third quarter, Fate Therapeutics showed an EPS of $0.86, compared to $0.45 from the year-ago quarter. The current stock performance of Fate Therapeutics shows a 52-week-high of $66.56 and a 52-week-low of $12.15. Moreover, at the end of the last trading period, the closing price was at $12.25.

    For Celularity Inc (NASDAQ:CELU), Oppenheimer downgraded the previous rating of Outperform to Perform. Celularity earned $0.03 in the third quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $13.19 and a 52-week-low of $1.10. Celularity closed at $1.28 at the end of the last trading period.

    According to Keefe, Bruyette & Woods, the prior rating for Jefferies Financial Group Inc (NYSE:JEF) was changed from Outperform to Market Perform. For the third quarter, Jefferies Financial Group had an EPS of $1.10, compared to year-ago quarter EPS of $1.50. The stock has a 52-week-high of $41.49 and a 52-week-low of $25.88. At the end of the last trading period, Jefferies Financial Group closed at $35.67.

    Canaccord Genuity downgraded the previous rating for Coupa Software Inc (NASDAQ:COUP) from Buy to Hold. In the third quarter, Coupa Software showed an EPS of $0.15, compared to $0.31 from the year-ago quarter. At the moment, the stock has a 52-week-high of $166.21 and a 52-week-low of $40.30. Coupa Software closed at $78.59 at the end of the last trading period.

    See all analyst ratings downgrades.

    Initiations

    EF Hutton initiated coverage on Golden Matrix Group Inc (NASDAQ:GMGI) with a Buy rating. The price target for Golden Matrix Group is set to $3.00. For the third quarter, Golden Matrix Group had an EPS of $0.02, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $10.72 and a 52-week-low of $1.89. At the end of the last trading period, Golden Matrix Group closed at $2.25.

    With a Buy rating, Mizuho initiated coverage on The Cooper Companies Inc (NYSE:COO). The price target seems to have been set at $375.00 for Cooper Companies. Cooper Companies earned $2.75 in the fourth quarter, compared to $3.28 in the year-ago quarter. The stock has a 52-week-high of $430.67 and a 52-week-low of $244.22. At the end of the last trading period, Cooper Companies closed at $328.69.

    With a Neutral rating, Mizuho initiated coverage on Glaukos Corp (NYSE:GKOS). The price target seems to have been set at $48.00 for Glaukos. In the third quarter, Glaukos showed an EPS of $0.45, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $64.49 and a 52-week-low of $33.33. At the end of the last trading period, Glaukos closed at $43.58.

    Mizuho initiated coverage on Boston Scientific Corp (NYSE:BSX) with a Neutral rating. The price target for Boston Scientific is set to $52.00. Boston Scientific earned $0.43 in the third quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.95 and a 52-week-low of $34.98. Boston Scientific closed at $46.08 at the end of the last trading period.

    Scotiabank initiated coverage on Ivanhoe Electric Inc (AMEX:IE) with a Sector Perform rating. The price target for Ivanhoe Electric is set to $14.00. The stock has a 52-week-high of $15.53 and a 52-week-low of $7.01. At the end of the last trading period, Ivanhoe Electric closed at $12.40.

    With a Buy rating, Mizuho initiated coverage on Alcon Inc (NYSE:ALC). The price target seems to have been set at $85.00 for Alcon. In the third quarter, Alcon showed an EPS of $0.50, compared to $0.54 from the year-ago quarter. The current stock performance of Alcon shows a 52-week-high of $88.78 and a 52-week-low of $55.21. Moreover, at the end of the last trading period, the closing price was at $68.28.

    Cantor Fitzgerald initiated coverage on Oncternal Therapeutics Inc (NASDAQ:ONCT) with an Overweight rating. The price target for Oncternal Therapeutics is set to $4.00. In the third quarter, Oncternal Therapeutics showed an EPS of $0.21, compared to $0.19 from the year-ago quarter. The stock has a 52-week-high of $2.72 and a 52-week-low of $0.69. At the end of the last trading period, Oncternal Therapeutics closed at $0.88.

    Janney Montgomery Scott initiated coverage on Markel Corp (NYSE:MKL) with a Buy rating. The price target for Markel is set to $1550.00. Markel earned $24.20 in the third quarter, compared to $15.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of $1519.24 and a 52-week-low of $1064.09. Markel closed at $1290.30 at the end of the last trading period.

    With an Overweight rating, Cantor Fitzgerald initiated coverage on X4 Pharmaceuticals Inc (NASDAQ:XFOR). The price target seems to have been set at $3.00 for X4 Pharmaceuticals. X4 Pharmaceuticals earned $0.26 in the third quarter, compared to $0.76 in the year-ago quarter. The current stock performance of X4 Pharmaceuticals shows a 52-week-high of $2.68 and a 52-week-low of $0.65. Moreover, at the end of the last trading period, the closing price was at $0.80.

    With a Buy rating, HC Wainwright & Co. initiated coverage on Applied Digital Corp (NASDAQ:APLD). The price target seems to have been set at $4.00 for Applied Digital. For the first quarter, Applied Digital had an EPS of $0.04, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $28.08 and a 52-week-low of $0.85. Applied Digital closed at $1.71 at the end of the last trading period.

    Loop Capital initiated coverage on Procore Technologies Inc (NYSE:PCOR) with a Buy rating. The price target for Procore Technologies is set to $70.00. Procore Technologies earned $0.09 in the third quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $83.70 and a 52-week-low of $40.00. At the end of the last trading period, Procore Technologies closed at $49.63.

    With a Neutral rating, Baird initiated coverage on Parsons Corp (NYSE:PSN). The price target seems to have been set at $50.00 for Parsons Corp. Parsons Corp earned $0.48 in the third quarter, compared to $0.44 in the year-ago quarter. The current stock performance of Parsons Corp shows a 52-week-high of $50.15 and a 52-week-low of $29.25. Moreover, at the end of the last trading period, the closing price was at $46.54.

    Evercore ISI Group initiated coverage on Global Business Travel Group Inc (NYSE:GBTG) with an Outperform rating. The price target for Global Business Travel is set to $8.00. The current stock performance of Global Business Travel shows a 52-week-high of $9.28 and a 52-week-low of $4.26. Moreover, at the end of the last trading period, the closing price was at $6.30.

    With an Outperform rating, RBC Capital initiated coverage on Brookfield Asset Management Ltd (NYSE:BAM). The price target seems to have been set at $35.00 for Brookfield Asset Mgmt. In the third quarter, Brookfield Asset Mgmt showed an EPS of $0.24, compared to $0.47 from the year-ago quarter. The stock has a 52-week-high of $62.47 and a 52-week-low of $26.76. At the end of the last trading period, Brookfield Asset Mgmt closed at $28.20.

    With an Outperform rating, Wedbush initiated coverage on Getty Images Holdings Inc (NYSE:GETY). The price target seems to have been set at $6.00 for Getty Images Holdings. The current stock performance of Getty Images Holdings shows a 52-week-high of $37.88 and a 52-week-low of $4.51. Moreover, at the end of the last trading period, the closing price was at $5.06.

    With a Buy rating, EF Hutton initiated coverage on Agenus Inc (NASDAQ:AGEN). The price target seems to have been set at $8.30 for Agenus. For the third quarter, Agenus had an EPS of $0.19, compared to year-ago quarter EPS of $0.72. The current stock performance of Agenus shows a 52-week-high of $3.62 and a 52-week-low of $1.25. Moreover, at the end of the last trading period, the closing price was at $2.44.

    See all analyst ratings initiations.

    Get the next $AGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN
    $ALC
    $APLD
    $BAM

    CompanyDatePrice TargetRatingAnalyst
    Procore Technologies Inc.
    $PCOR
    2/5/2026$87.00 → $67.00Outperform
    BMO Capital Markets
    Brookfield Asset Management Inc
    $BAM
    2/5/2026$58.00Market Perform → Outperform
    BMO Capital Markets
    The Cooper Companies Inc.
    $COO
    2/3/2026$100.00 → $99.00Buy
    Needham
    Alcon Inc.
    $ALC
    1/30/2026Mkt Perform
    William Blair
    Alcon Inc.
    $ALC
    1/20/2026Hold → Buy
    Deutsche Bank
    Alcon Inc.
    $ALC
    1/9/2026Buy → Hold
    Stifel
    Applied Digital Corporation
    $APLD
    1/7/2026$99.00Buy
    Arete
    Procore Technologies Inc.
    $PCOR
    1/5/2026$90.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $AGEN
    $ALC
    $APLD
    $BAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Handler Richard B received a gift of 81,076 shares and gifted 81,076 shares, increasing direct ownership by 0.60% to 13,550,602 units (SEC Form 4)

    4 - Jefferies Financial Group Inc. (0000096223) (Issuer)

    2/11/26 9:33:01 PM ET
    $JEF
    Investment Bankers/Brokers/Service
    Finance

    CHAIRMAN & CEO Burns Thomas William received a gift of 67,353 shares, exercised 166,000 shares at a strike of $30.92 and gifted 67,353 shares, increasing direct ownership by 63% to 255,621 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    2/10/26 8:14:18 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    President Zhang Jason Gechen was granted 500,000 shares, increasing direct ownership by 36% to 1,908,165 units (SEC Form 4)

    4 - Applied Digital Corp. (0001144879) (Issuer)

    2/9/26 4:56:26 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    $AGEN
    $ALC
    $APLD
    $BAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets reiterated coverage on Procore Technologies with a new price target

    BMO Capital Markets reiterated coverage of Procore Technologies with a rating of Outperform and set a new price target of $67.00 from $87.00 previously

    2/5/26 7:01:15 AM ET
    $PCOR
    Computer Software: Prepackaged Software
    Technology

    Brookfield Asset Mgmt upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Brookfield Asset Mgmt from Market Perform to Outperform and set a new price target of $58.00

    2/5/26 6:50:02 AM ET
    $BAM
    Other Consumer Services
    Consumer Discretionary

    Needham reiterated coverage on Cooper with a new price target

    Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously

    2/3/26 7:02:57 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $AGEN
    $ALC
    $APLD
    $BAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $AGEN
    $ALC
    $APLD
    $BAM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Getty Images and NASCAR Renew Multi-Year Agreement

    A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Getty Images (NYSE:GETY), a preeminent global visual content creator and marketplace, today announced the renewal of its long-standing partnership with NASCAR, extending its role as NASCAR's Official Photography Partner, a designation it has held since 2006. The agreement sees Getty Images' team of specialized motorsport photographers deliver high-quality imagery from all races and events in the NASCAR series, including NASCAR Cup Series™, NASCAR O'Reilly Auto Parts Series™, and NASCAR CRAFTSMAN Truck Series™. With exclusive, behind-the-scenes access, Getty

    2/12/26 8:00:00 AM ET
    $GETY
    Real Estate

    SMBC Group's Yoshihiro Hyakutome Nominated to Jefferies Board of Directors As Focus Intensifies on Global Strategic Alliance

    Jefferies Financial Group Inc. ("Jefferies") and Sumitomo Mitsui Financial Group, Inc. and its wholly owned subsidiary Sumitomo Mitsui Banking Corporation (collectively, "SMBC Group") announced today that Yoshihiro Hyakutome, Deputy President, Executive Officer and Co-Head of the Global Business Unit of SMBC Group, has been identified by SMBC Group as a candidate to be a member of the Jefferies Board of Directors, replacing Toru Nakashima, CEO of SMBC Group. Mr. Nakashima has served as a board member since August 2024, upon SMBC Group's investment in Jefferies exceeding 10%, and will be serving until the end of his term. As the Global Strategic Alliance between Jefferies and SMBC Group be

    2/11/26 4:15:00 PM ET
    $JEF
    Investment Bankers/Brokers/Service
    Finance

    Parsons Reports Fourth Quarter and Fiscal Year 2025

    Q4 2025 Financial Highlights  Q4 revenue of $1.6 billion decreased 8% year-over-year and 10% on an organic basisTotal revenue growth of 11% and 8% on an organic basis excluding confidential contractNet income of $56 million increased 3% year-over-year, a fourth quarter recordRecord adjusted EBITDA of $153 million increased 5%; adjusted EBITDA margin of 9.6%Cash flow from operations increased 32% to $168 millionBook-to-bill ratio of 0.9x and continued streak of TTM book-to-bill ratio of 1.0x or greater in every quarter since IPO Fiscal Year 2025 Highlights FY25 revenue of $6.4 billion, decreased 6% year-over-year and 9% on an organic basisTotal revenue growth of 12% and 8% on an organic b

    2/11/26 6:30:00 AM ET
    $PSN
    EDP Services
    Technology

    $AGEN
    $ALC
    $APLD
    $BAM
    SEC Filings

    View All

    SEC Form PRE 14A filed by Jefferies Financial Group Inc.

    PRE 14A - Jefferies Financial Group Inc. (0000096223) (Filer)

    2/11/26 4:33:38 PM ET
    $JEF
    Investment Bankers/Brokers/Service
    Finance

    SEC Form DEFA14A filed by Jefferies Financial Group Inc.

    DEFA14A - Jefferies Financial Group Inc. (0000096223) (Filer)

    2/11/26 4:26:15 PM ET
    $JEF
    Investment Bankers/Brokers/Service
    Finance

    Jefferies Financial Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Jefferies Financial Group Inc. (0000096223) (Filer)

    2/11/26 4:24:24 PM ET
    $JEF
    Investment Bankers/Brokers/Service
    Finance

    $AGEN
    $ALC
    $APLD
    $BAM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $AGEN
    $ALC
    $APLD
    $BAM
    Leadership Updates

    Live Leadership Updates

    View All

    SMBC Group's Yoshihiro Hyakutome Nominated to Jefferies Board of Directors As Focus Intensifies on Global Strategic Alliance

    Jefferies Financial Group Inc. ("Jefferies") and Sumitomo Mitsui Financial Group, Inc. and its wholly owned subsidiary Sumitomo Mitsui Banking Corporation (collectively, "SMBC Group") announced today that Yoshihiro Hyakutome, Deputy President, Executive Officer and Co-Head of the Global Business Unit of SMBC Group, has been identified by SMBC Group as a candidate to be a member of the Jefferies Board of Directors, replacing Toru Nakashima, CEO of SMBC Group. Mr. Nakashima has served as a board member since August 2024, upon SMBC Group's investment in Jefferies exceeding 10%, and will be serving until the end of his term. As the Global Strategic Alliance between Jefferies and SMBC Group be

    2/11/26 4:15:00 PM ET
    $JEF
    Investment Bankers/Brokers/Service
    Finance

    Applied Digital Appoints Co-Founder Jason Zhang as President

    DALLAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ:APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads, today announced the appointment of its co-founder and current Chief Strategy Officer, Jason Zhang, as the company's President. As one of the founders of Applied Digital, Mr. Zhang has been instrumental in fueling the company's innovation, working closely with co-founder Wes Cummins. The appointment reflects the role Mr. Zhang has long played in shaping the company's strategy and long-term growth trajectory. As President, Mr. Zhang

    1/15/26 8:00:00 AM ET
    $APLD
    Finance: Consumer Services
    Finance

    Parsons Acquires Altamira Technologies Corporation

    CHANTILLY, Va., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE:PSN) announced today that it has acquired Northern Virginia-based Altamira Technologies Corporation in a transaction valued up to $375 million. Founded in 1999, Altamira enhances Parsons' defense and intelligence portfolio by delivering advanced analytics, signals intelligence (SIGINT), cyber, missile warning, and space capabilities, complementing the company's strengths in all‑domain technology integration and Indo‑Pacific operations, and expanding with Intelligence Community (IC) customers. "Acquiring Altamira is a strategic accelerator for our national security growth strategy, strengthening Parsons' ability to

    1/15/26 6:30:00 AM ET
    $PSN
    EDP Services
    Technology

    $AGEN
    $ALC
    $APLD
    $BAM
    Financials

    Live finance-specific insights

    View All

    Parsons Reports Fourth Quarter and Fiscal Year 2025

    Q4 2025 Financial Highlights  Q4 revenue of $1.6 billion decreased 8% year-over-year and 10% on an organic basisTotal revenue growth of 11% and 8% on an organic basis excluding confidential contractNet income of $56 million increased 3% year-over-year, a fourth quarter recordRecord adjusted EBITDA of $153 million increased 5%; adjusted EBITDA margin of 9.6%Cash flow from operations increased 32% to $168 millionBook-to-bill ratio of 0.9x and continued streak of TTM book-to-bill ratio of 1.0x or greater in every quarter since IPO Fiscal Year 2025 Highlights FY25 revenue of $6.4 billion, decreased 6% year-over-year and 9% on an organic basisTotal revenue growth of 12% and 8% on an organic b

    2/11/26 6:30:00 AM ET
    $PSN
    EDP Services
    Technology

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Markel Group reports 2025 financial results

    RICHMOND, Va., Feb. 4, 2026 /PRNewswire/ -- Markel Group Inc. (NYSE:MKL) today reported its financial results for the quarter and year ended December 31, 2025. "In 2025, the Markel Group delivered meaningful progress. Operating income was $3.2 billion and adjusted operating income exceeded $2.3 billion, with every reportable segment making meaningful contributions," said Tom Gayner, Chief Executive Officer. "Within Markel Insurance, we took a series of decisive actions to simplify and refocus the business. Thank you to that team, and to everyone across the Markel Group. By sta

    2/4/26 4:35:00 PM ET
    $MKL
    Property-Casualty Insurers
    Finance

    $AGEN
    $ALC
    $APLD
    $BAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Golden Matrix Group Inc.

    SC 13D/A - Golden Matrix Group, Inc. (0001437925) (Subject)

    11/29/24 5:00:05 PM ET
    $GMGI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Applied Digital Corporation

    SC 13D/A - Applied Digital Corp. (0001144879) (Subject)

    11/29/24 4:20:07 PM ET
    $APLD
    Finance: Consumer Services
    Finance